Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Johnson and Johnson (France) Company Profile

15:37 EDT 19th April 2014 | BioPortfolio

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you and the ones you love lead longer, healthier lives.

These companies are organized into three global business units:

Central Nervous System and Internal Medicine

This business unit develops medicines for an array of health problems, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; and infectious diseases.

B.I.O. (Biotechnology, Immunology & Oncology)

This business unit develops traditional and biologic medicines to treat autoimmune disorders, such as rheumatoid arthritis, psoriasis, and Crohn’s disease; a wide range of cancers; and blood disorders, such as anemia.

Virology

This business unit develops medicines for the treatment of infectious diseases, such as HIV/AIDS, hepatitis C and tuberculosis.

Location

rue camille desmoulins
issy les moulineaux cedex 9
F-92787
France

Contact

Phone: 33-155004174


News Articles [1532 Associated News Articles listed on BioPortfolio]

Johnson & Johnson appoints Yale project team to run data sharing scheme

Johnson & Johnson has appointed an independent US body to field requests from researchers for access to its clinical trials data.Janssen, the pharmaceutical arm of Johnson & Johnson, has entered into....

Intrexon, Johnson & Johnson partner on consumer health products

Intrexon Corp. has signed an alliance with Johnson & Johnson’s Innovation Center and Johnson & Johnson Consumer & Personal Products WW (part of Johnson & Johnson Consumer Cos. Inc.) for the creation...

U.S. Drug Sales Drive 37% 4Q Profit Jump at Johnson & Johnson

Johnson & Johnson posted profits of $1.24 per share on revenues of $18.4 billion, beating on both lines in the fourth quarter. 

Assembly Pharmaceuticals completes its Series A round

Johnson & Johnson’s Johnson & Johnson Develoment Corp. and Johnson & Johnson Innovation made an undisclosed investment in what is believed to be Assembly Pharmaceuticals Inc.’s Series A venture ro...

Table 1: Johnson & Johnson Innovation's deal pipeline

Translational Notes: Biotech kibbutz Table 1. Johnson & Johnson Innovation's deal pipeline. Source: Johnson & Johnson press release J&J site Partner Disease area Project Boston Innovation Center The U...

Johnson & Johnson profitiert von Medikamentennachfrage

Der US-Konsumgüter- und Medizintechnikproduzent Johnson & Johnson (J&J) hat sich im vierten Quartal dank starker Zuwächse im Pharmageschäft besser geschlagen als erwartet. Der Gewinn legte in den ....

Why Johnson & Johnson Moved From 'Buy' To 'Hold'

author name submits:Man, wouldn't it be nice to go back in time two years and load up on Johnson & Johnson (JNJ) shares in the $60-$65 range when everyone was ragging on the company's sustained se...

Johnson & Johnson Tries New Model for Data Transparency

Xconomy | Johnson & Johnson today announced that an independent group at Yale will be empowered to review and grant scientific requests to see the full results of any clinical trial in the company...

PubMed Articles [245 Associated PubMed Articles listed on BioPortfolio]

Johnson & Johnson appoints Yale project team to run data sharing scheme.

J&J partners with yale to share trial data.

Johnson & Johnson (J&J) joins GlaxoSmithKline, Pfizer, Roche, and other pharmaceutical companies in sharing its clinical trial data with researchers. J&J, however, is the only company to enlist an ind...

Late onset imatinib-induced Stevens-Johnson syndrome.

Imatinib, a BCR-ABL tyrosine kinase inhibitor, is known to cause mild to moderate cutaneous reactions in up to approximately 20% of patients. It rarely causes severe reactions, such as Stevens-Johnson...

Stevens Johnson Syndrome in a patient undergoing gynaecological brachytherapy: An association or an incident?

Stevens Johnson Syndrome and Erythema Multiforme are hypersensitivity skin reactions generally arising in the context of multiple causes. Radiation therapy is considered to be one of these causes, alt...

Evaluation of conjunctival bacterial flora in patients with Stevens-Johnson Syndrome.

To determine the conjunctival bacterial flora present in patients with Stevens-Johnson syndrome.

Clinical Trials [142 Associated Clinical Trials listed on BioPortfolio]

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Extracorporeal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allow...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20...

Companies [429 Associated Companies listed on BioPortfolio]

Johnson and Johnson

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnso...

Johnson & Johnson Innovation

The London Innovation Centre is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation focuses on accelerating early i...

Johnson & Johnson (China) Investment Co., Ltd.

Johnson & Johnson (China) Investment Co., Ltd. is a foreign investment entity established in China by Johnson & Johnson in 1998. For more information about Johnson & Johnson and its operating unit...

JOHNSON'S(R) Brand

JOHNSON'S® Brand from Johnson & Johnson Consumer Products Company, Division of Johnson & Johnson Consumer Companies, Inc., has a long tradition of providing pure, mild, gentle and clinically-proven p...

JANSSEN-ORTHO INC

Since 1961 Janssen-Cilag has been a member of the Johnson & Johnson family of companies. Founded in 1886, Johnson & Johnson today is the world's most comprehensive manufacturer of healthcare products...

More Information about "Johnson and Johnson (France)" on BioPortfolio

We have published hundreds of Johnson and Johnson (France) news stories on BioPortfolio along with dozens of Johnson and Johnson (France) Clinical Trials and PubMed Articles about Johnson and Johnson (France) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Johnson and Johnson (France) Companies in our database. You can also find out about relevant Johnson and Johnson (France) Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement